Trends in Metastatic Breast and Prostate Cancer--Lessons in Cancer Dynamics.
about
Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of LiteratureProstate cancer screening in Brazil: should it be done or not?Prostate cancer screening with prostate-specific antigen: A guide to the guidelinesPopulation-based screening for cancer: hope and hype.Truth or Spin? Disease Definition in Cancer Screening.Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer.Mass spectrometry analysis shows the biosynthetic pathways supported by pyruvate carboxylase in highly invasive breast cancer cells.Conquering Metastatic Breast Cancer.Screening mammography: sparing the emperor's blushes.Prevention of breast cancer by RANKL/RANK blockade.Prostate Cancer Prevention: Concepts and Clinical Trials.What's new in screening in 2015?Metastatic breast cancer: The Odyssey of personalization.The impact of local treatment of the primary tumor site in node positive and metastatic prostate cancer patients.PRECISION MANAGEMENT OF LOCALIZED PROSTATE CANCER.Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis.Trends in stage-specific breast cancer incidence in New South Wales, Australia: insights into the effects of 25 years of screening mammography.Is prostate cancer stage migration continuing for black men in the PSA era?Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population.Molecular characterization of breast cancer CTCs associated with brain metastasis.NUSAP1 promotes invasion and metastasis of prostate cancerProstate cancer: what is the right message?Who and when should we screen for prostate cancer? Interviews with key opinion leaders.Tissue-based biomarkers in prostate cancer.De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.PSA screening for prostate cancer.Future directions in prostate cancer testing: a comment upon results from the prospective population-based diagnostic STHLM3 study-Grönberg H et al. Lancet Oncology. 2015 Nov 9; doi:10.1016/S1470-2045(15)00361-7.New agents for the management of resistant metastatic breast cancer.Survival after recurrence of stage I-III breast, colorectal, or lung cancer.Analysis of utilization patterns and associated costs of the breast imaging and diagnostic procedures after screening mammography.Trends in the Incidence of Fatal Prostate Cancer in the United States by Race.Are Ocular and Ocular Adnexal Cancers Overdiagnosed? Historical Perspectives on Diagnosis.Plasma ghrelin O-acyltransferase (GOAT) enzyme levels: A novel non-invasive diagnosis tool for patients with significant prostate cancer
P2860
Q26750735-3A88ED9D-6B2D-4657-B13E-6C911923F3B9Q28068688-EB93125D-8E7F-4B2C-A1A9-537F698D6B5FQ28070347-5A78214A-EFF0-4F07-9A42-0201682A3198Q30251601-778CD174-CF41-4E7C-B817-D6C567A845B8Q30401159-EBC55144-E8ED-49A8-A429-8EDE0CF312D9Q33816617-BE98B996-46AE-427B-BF71-A429A0A80BACQ36051375-08393845-01A2-44E4-B5EB-0348A4E8D030Q36204898-C6B61974-D282-43B3-A844-E7DBC8F00145Q37125037-EDAB557D-7BCD-4FD3-BAD2-8B82C9D42620Q37373148-54114BD4-51F4-4C5C-8FB9-226339044C8BQ37457322-CD2FDAAC-8EE7-4BBE-890D-08FB52262D58Q38766396-3CB98294-AAC2-4FDA-A353-1FB7E8430437Q38871819-A431DFEF-4557-4EA0-85BF-BAAD4C10689EQ38901163-517A0DD1-76D2-4BCA-947C-99BC90762C36Q38990182-74FE8290-E37C-4B9D-B681-72A6452FB42DQ39108592-24D08C6B-BB0D-414E-841C-B36F46CCACF4Q39703687-09480CE9-E9C8-45D9-A3FD-51F0C4256608Q40077849-D3274EEA-AAF3-40B0-9942-2DBF2E2586D8Q40377882-17058BDB-1FA6-4C93-AD7C-07524A1F021FQ40633654-D95B299D-204A-4AAD-A709-3BE9356810DFQ41242728-123769D2-C512-41A6-A7BC-63AD60CAE949Q42244850-2F15C6D1-A5FA-4EBC-975A-ED5FECD15CC8Q42765159-7E365FE7-9B21-494B-BE75-F3895D393346Q43152601-F6CE9DA8-3A63-40EA-9645-AC3611C3AD82Q47144748-F7D67019-A305-4006-A5C0-1F66FE5906DFQ47232243-115BB6F1-AC17-467B-A983-48E721C5E5FBQ47700583-67649EF8-7299-42B5-9CBB-35FAB39BC961Q48080052-801E3B84-9C5E-403A-9B68-BE5407D80524Q48240854-5AAF9DE1-AB4E-470B-910B-E156E6804882Q50528546-3F9005B0-BD7F-4C95-B747-F4044AEE0C20Q52606246-42701F89-306C-452E-BED4-E1F7AD42790EQ53049418-D9CE7463-8C3C-4D86-B25C-C156931EC8D0Q54532255-DF5EF3CF-C9C8-48AB-8F89-0237CA135B7EQ58760499-090D7162-39A3-4638-BB83-95A1E2DF3048
P2860
Trends in Metastatic Breast and Prostate Cancer--Lessons in Cancer Dynamics.
description
2015 nî lūn-bûn
@nan
2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Trends in Metastatic Breast and Prostate Cancer--Lessons in Cancer Dynamics.
@ast
Trends in Metastatic Breast and Prostate Cancer--Lessons in Cancer Dynamics.
@en
Trends in Metastatic Breast and Prostate Cancer--Lessons in Cancer Dynamics.
@nl
type
label
Trends in Metastatic Breast and Prostate Cancer--Lessons in Cancer Dynamics.
@ast
Trends in Metastatic Breast and Prostate Cancer--Lessons in Cancer Dynamics.
@en
Trends in Metastatic Breast and Prostate Cancer--Lessons in Cancer Dynamics.
@nl
prefLabel
Trends in Metastatic Breast and Prostate Cancer--Lessons in Cancer Dynamics.
@ast
Trends in Metastatic Breast and Prostate Cancer--Lessons in Cancer Dynamics.
@en
Trends in Metastatic Breast and Prostate Cancer--Lessons in Cancer Dynamics.
@nl
P2093
P356
P1476
Trends in Metastatic Breast and Prostate Cancer--Lessons in Cancer Dynamics.
@en
P2093
David H Gorski
H Gilbert Welch
Peter C Albertsen
P304
P356
10.1056/NEJMP1510443
P407
P577
2015-10-01T00:00:00Z